137 related articles for article (PubMed ID: 8262866)
1. In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
J Antimicrob Chemother; 1993 Sep; 32(3):445-51. PubMed ID: 8262866
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
Dhople AM; Namba K
J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
[TBL] [Abstract][Full Text] [Related]
3. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
J Antimicrob Chemother; 1995 Apr; 35(4):463-71. PubMed ID: 7628981
[TBL] [Abstract][Full Text] [Related]
4. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA; Gardner GD
Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
Dhople AM; Dimova V
Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
[TBL] [Abstract][Full Text] [Related]
6. The activity of rifabutin against Mycobacterium leprae in armadillos.
Dhople AM; Williams SL
Int J Antimicrob Agents; 1997 Jan; 9(3):169-73. PubMed ID: 9552713
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae.
Dhople AM; Ibanez MA
Antimicrob Agents Chemother; 1995 Sep; 39(9):2116-9. PubMed ID: 8540726
[TBL] [Abstract][Full Text] [Related]
8. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Matsuoka M; Kashiwabara Y; Namisato M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
[TBL] [Abstract][Full Text] [Related]
9. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Dhople AM; Namba K
Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
Dhople AM; Lamoureux LC; Gardner GD
Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans.
Thangaraj HS; Adjei O; Allen BW; Portaels F; Evans MR; Banerjee DK; Wansbrough-Jones MH
J Antimicrob Chemother; 2000 Feb; 45(2):231-3. PubMed ID: 10660507
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae.
Franzblau SG; White KE
Antimicrob Agents Chemother; 1990 Feb; 34(2):229-31. PubMed ID: 2183714
[TBL] [Abstract][Full Text] [Related]
13. The activity of rifabutin against Mycobacterium leprae.
Yoder LJ; Jacobson RR; Hastings RC
Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
Dhople AM
Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
[TBL] [Abstract][Full Text] [Related]
15. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
Dhople AM; Ibanez MA
Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
[TBL] [Abstract][Full Text] [Related]
16. Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
Pellegrin I; Maugein J; Lapeyre C; Barbeau P; Leng B; Pellegrin JL
J Antimicrob Chemother; 1996 Mar; 37(3):501-10. PubMed ID: 9182107
[TBL] [Abstract][Full Text] [Related]
17. [In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Gidoh M
Nihon Hansenbyo Gakkai Zasshi; 2007 Feb; 76(1):11-7. PubMed ID: 17315747
[TBL] [Abstract][Full Text] [Related]
18. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae.
Cambau E; Perani E; Guillemin I; Jamet P; Ji B
Lancet; 1997 Jan; 349(9045):103-4. PubMed ID: 8996430
[No Abstract] [Full Text] [Related]
19. Search for newer antileprosy drugs.
Dhople AM
Indian J Lepr; 2000; 72(1):5-20. PubMed ID: 10935183
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae.
Dhople AM
Int J Antimicrob Agents; 1999 Aug; 12(4):319-23. PubMed ID: 10493608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
